Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
Key facts
- Who runs it
- Complejo Hospitalario Universitario de Albacete
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 230 people enrolled
- Started
- 21 Feb 2024
- Ended
- 25 Apr 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Calcifediol
- Record updated
- 5 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Admitted to the hospital CHUA
- Meet the SARS-CoV-2 diagnostic criteria with positive PCR
- They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol)
Who cannot take part
- Patients with other serious intercurrent diseases (eg advanced oncological pathology)
- Patients who do not receive the full first dose of Calcifediol within the first 72 hours
- Patients for whom electronic medical record data cannot be collected
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Complejo Hospitalario Universitario de Albacete" (CHUA). Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.
The 2 groups in the trial
- Patients treated with calcifediol
Patients admitted to the CHUA, due to COVID-19 \[respiratory infection confirmed by radiographic pattern of viral pneumonia and positive polymerase chain reaction (PCR)/antigen for SARS-CoV-2\] treated with calcifediol
Treatment: Calcifediol
- Patients not treated with calcifediol
Patients admitted to the CHUA, due to COVID-19 (respiratory infection confirmed by radiographic pattern of viral pneumonia and positive PCR/antigen for SARS-CoV-2) not treated with calcifediol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Inclusion of Calcifediol in the Hospital Therapeutic Protocol for Treatment of SARS-CoV-2 Disease (COVID-19). Mortality Analysis. Retrospective Study.
- Record updated
- 5 June 2025